Protagonist Therapeutics Inc PTGX:NASDAQ

Last Price$13.47Cboe Real-Time Last Sale as of 12:01PM ET 1/31/23
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.48(3.70%)
Bid (Size)$13.46 (10)
Ask (Size)$13.51 (22)
Day Low / High$12.91 - 13.61
Volume316.4 K
  • Latest Stories
  • Commentary and Analysis
--HC Wainwright Lowers Price Target on Protagonist Therapeutics to $33 From $50, Maintains Buy Rating
9:40AM ET 11/10/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

JMP Securities Reinstates Protagonist Therapeutics at Market Outperform With $21 Price Target
6:01AM ET 8/25/2022 MT Newswires

Protagonist Therapeutics (PTGX) has an average rating of outperform and price targets ranging from $21 to $50, according to analysts polled by Capital IQ....

Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reiterates Overweight Rating
6:52AM ET 5/18/2022 MT Newswires

Protagonist Therapeutics (PTGX) has an average rating of buy and price targets ranging from $30 to $60, according to analysts polled by Capital IQ. (MT...

--SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $30 from $50, Keeps Outperform Rating
10:00AM ET 5/05/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Protagonist Therapeutics' Shares Plummet After Reporting Trial Data for Inflammatory Bowel Disease Treatment
2:54PM ET 4/26/2022 MT Newswires

Protagonist Therapeutics (PTGX) shares slumped 53% by Tuesday afternoon, a day after the biopharmaceutical company said a phase 2 study of its proposed...

Top Midday Decliners
1:50PM ET 4/26/2022 MT Newswires

Protagonist Therapeutics (PTGX) shares slumped 49% amid heavy trading after the company reported topline data from a phase 2 trial of PN-943 in ulcerative...

Top Premarket Decliners
7:55AM ET 4/26/2022 MT Newswires

Protagonist Therapeutics (PTGX) shares slumped 33% after the company reported topline data from a phase 2 trial of PN-943 in ulcerative colitis. InMed...

Sector Update: Health Care Stocks Fading Late, Stop Just Shy of Higher Close
3:56PM ET 4/14/2022 MT Newswires

Health care stocks were narrowly lower this afternoon, with the NYSE Health Care Index slipping 0.1% and the SPDR Health Care Select Sector ETF (XLV) down...

Top Midday Decliners
1:58PM ET 4/14/2022 MT Newswires

Protagonist Therapeutics (PTGX) said it received a letter from the Food and Drug Administration indicating the regulator's intention to rescind...

Update: Protagonist Stock Tumbles Thursday as FDA Plans to Rescind Rusfertide Breakthrough Designation
1:36PM ET 4/14/2022 MT Newswires

(Updates with the stock move in the second paragraph and headline.) Protagonist Therapeutics (PTGX) said late on Wednesday it received a letter from the...